Stopping Opioid Overuse in Obstetrics To Halt Exposure Trial (SOOOTHE)
Pain, Postoperative, Opioid Use
About this trial
This is an interventional treatment trial for Pain, Postoperative
Eligibility Criteria
Inclusion Criteria:
- Unlabored, scheduled primary or repeat cesarean delivery
- Cesarean performed by obstetrician or surgically-trained family medicine physician
- Ability to complete numeric pain scale assessment and surveys
- Patients who do not speak English but are able to converse via an interpreter both in person and by phone
Exclusion Criteria:
- Complications requiring return to the operating room
- Unscheduled deliveries
- <18 years old, >45 years old
- Twin deliveries
- Preterm deliveries (<37 wks)
- Current or previous history of opioid-substance use disorder according to patient report or medical chart
- Prescription of opioid medication filled in previous 30 days prior to delivery according to patient report, documentation in electronic medical record, or documentation in the prescription drug monitoring program
- Allergy to local anesthetics or NSAIDs
- Cardiovascular disease, eg arrhythmia, or ASA (American Society of Anesthesiologists) Class III or higher
- Diagnosis of liver disorder or dysfunction including fatty liver of pregnancy, preeclampsia with severe features including liver or kidney involvement
- Known significant renal disease, oliguria, or Cr >1.1.
- Platelet count less than or equal to 90k or rapid decline in third trimester or other coagulopathy
- Infection overlying the regional anesthesia site
- Hypovolemia prohibiting regional anesthesia
- General anesthesia
Sites / Locations
- Truman Medical Center - Lakewood
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Treatment
Control
The transversus abdominis plane block is a procedure involving injection of a local anesthetic solution into the abdominal plane between the internal oblique muscle and the transversus abdominis muscle. In our institution, this is done under ultrasound guidance which is the current standard to improve efficacy and limit complications. Liposomal bupivacaine uses an innovative technology consisting of lipid-based particles containing active pharmaceutical agent (bupivacaine) which extends the duration of the medication through a process of gradual release for metabolism.This drug delivery technology extends the duration of action to up to 96 hours when given at a dose of 266 mg liposomal bupivacaine admixed with 30 ml of bupivacaine 0.25% and 30 ml of saline. Forty ml of solution is deposited on the left side of the abdomen and 40 ml on the right.
The transversus abdominis plane block will be performed under ultrasound guidance with deposition of 80 ml of saline (40 ml on either side).